Evidence map›Paper›PMID 39468666›Full record

ArticleStem cell research & therapy2024

Multi-omics evaluation of clinical-grade human umbilical cord-derived mesenchymal stem cells in synergistic improvement of aging related disorders in a senescence-accelerated mouse model.

Jiabian Lian, Lu Xia, Guohao Wang, Weijing Wu, Ping Yi, Meilin Li, Xufeng Su, Yushuo Chen, Xun Li, Fei Dou and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Impact of CaInternational journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jiabian Lian *Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
Lu Xia *Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China. Luxia@xmu.edu.cn.ORCID 0000-0002-0124-3843
Guohao Wang *Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.
Weijing WuLaboratory of Nutrition and Food Safety, Xiamen Medical College, Xiamen, Fujian, China.
Ping YiLaboratory of Nutrition and Food Safety, Xiamen Medical College, Xiamen, Fujian, China.
Meilin LiLaboratory of Nutrition and Food Safety, Xiamen Medical College, Xiamen, Fujian, China.
Xufeng SuLaboratory of Nutrition and Food Safety, Xiamen Medical College, Xiamen, Fujian, China.
Yushuo ChenLaboratory of Nutrition and Food Safety, Xiamen Medical College, Xiamen, Fujian, China.
Xun LiCenter for Precision Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China. xli2001@xmu.edu.cn.
Fei DouState Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, College of Life Sciences, Beijing Normal University, Beijing, 100875, China. douf@bnu.edu.cn.
Zhanxiang WangXiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China. wangzx@xmu.edu.cn.

Funding

Health science and technology project of Fujian Province 2023QNB003Key Healthcare Projects of Xiamen City 3502Z20234008Natural Science Foundation of Xiamen 3502Z202372072Natural Science Foundation of Xiamen 3502Z20244ZD1009Xiamen Cell Therapy Research Center 3502220214001Xiamen Medical College Undergraduate Innovation and Entrepreneurship Training Program 2022Xiamen Medical College Undergraduate Innovation and Entrepreneurship Training Program 202212631066
6 · The paper itself

Abstract

backgroundThe prevalence of age-related disorders, particularly in neurological and cardiovascular systems, is an increasing global health concern. Mesenchymal stem cell (MSC) therapy, particularly using human umbilical cord-derived MSCs (HUCMSCs), has shown promise in mitigating these disorders. This study investigates the effects of HUCMSCs on aging-related conditions in a senescence-accelerated mouse model (SAMP8), with a focus on DNA damage, gut microbiota alterations, and metabolic changes.

methodsSAMP8 mice were treated with clinical-grade HUCMSCs via intraperitoneal injections. Behavioral and physical assessments were conducted to evaluate cognitive and motor functions. The Single-Strand Break Mapping at Nucleotide Genome Level (SSiNGLe) method was employed to assess DNA single-strand breaks (SSBs) across the genome, with particular attention to exonic regions and transcription start sites. Gut microbiota composition was analyzed using 16S rRNA sequencing, and carboxyl metabolomic profiling was performed to identify changes in circulating metabolites.

resultsHUCMSC treatment significantly improved motor coordination and reduced anxiety in SAMP8 mice. SSiNGLe analysis revealed a notable reduction in DNA SSBs in MSC-treated mice, especially in critical genomic regions, suggesting that HUCMSCs may mitigate age-related DNA damage. The functional annotation of the DNA breaktome indicated a potential link between reduced DNA damage and altered metabolic pathways. Additionally, beneficial alterations in gut microbiota were observed, including an increase in short-chain fatty acid (SCFA)-producing bacteria, which correlated with improved metabolic profiles.

conclusionThe administration of HUCMSCs in SAMP8 mice not only reduces DNA damage but also induces favorable changes in gut microbiota and metabolism. The observed alterations in DNA break patterns, along with specific changes in microbiota and metabolic profiles, suggest that these could serve as potential biomarkers for evaluating the efficacy of HUCMSCs in treating age-related disorders. This highlights a promising avenue for the development of new therapeutic strategies that leverage these biomarkers, to enhance the effectiveness of HUCMSC-based treatments for aging-associated diseases.

Indexed as

AgingDisease Models, AnimalMesenchymal Stem CellsUmbilical CordAnimalsDNA DamageGastrointestinal MicrobiomeHumansMaleMesenchymal Stem Cell TransplantationMiceMultiomicsAgingDNA breaksFaecal microbiomeHuman umbilical cord mesenchymal stem cellsMetabolomicsSenescence-accelerated mouse model

Identifiers

PMID39468666
PMCPMC11520580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.